一名慢性淋巴细胞白血病患者在接受依鲁替尼治疗期间出现自发性前房积血。
Spontaneous Hyphema during Ibrutinib Treatment in a CLL Patient.
作者信息
Aldecoa Kim Abbegail Tan, Macaraeg Chef Stan L, Dadlani Akash, Yadlapalli Sri
机构信息
Department of Internal Medicine, Trinity Health Oakland, Pontiac, MI, USA.
Wayne State University, Detroit, MI, USA.
出版信息
Case Rep Hematol. 2023 Dec 14;2023:1691996. doi: 10.1155/2023/1691996. eCollection 2023.
Ibrutinib is an oral, first-line, targeted therapy for chronic lymphocytic leukemia (CLL). Commonly reported adverse events are diarrhea, fatigue, and musculoskeletal pain, but rarely it has been associated with visual disturbances. Here, we present a rare case of spontaneous hyphema in a 60-year-old patient with a known diagnosis of CLL on ibrutinib treatment.
依鲁替尼是一种用于慢性淋巴细胞白血病（CLL）的口服一线靶向治疗药物。常见的不良事件包括腹泻、疲劳和肌肉骨骼疼痛，但它很少与视觉障碍相关。在此，我们报告一例60岁已知诊断为CLL且正在接受依鲁替尼治疗的患者发生自发性前房积血的罕见病例。
Zotero 插件